KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $117.6 million.

  • Biogen's Other Operating Expenses fell 5834.22% to $117.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$33.6 million, marking a year-over-year decrease of 11280.49%. This contributed to the annual value of -$33.6 million for FY2025, which is 13792.33% down from last year.
  • Per Biogen's latest filing, its Other Operating Expenses stood at $117.6 million for Q4 2025, which was down 5834.22% from -$34.1 million recorded in Q3 2025.
  • Biogen's Other Operating Expenses' 5-year high stood at $964.1 million during Q4 2021, with a 5-year trough of -$502.9 million in Q3 2021.
  • Moreover, its 5-year median value for Other Operating Expenses was $10.8 million (2021), whereas its average is $51.5 million.
  • As far as peak fluctuations go, Biogen's Other Operating Expenses tumbled by 183413.79% in 2021, and later soared by 213442.62% in 2023.
  • Over the past 5 years, Biogen's Other Operating Expenses (Quarter) stood at $964.1 million in 2021, then crashed by 101.27% to -$12.2 million in 2022, then surged by 2134.43% to $248.2 million in 2023, then rose by 13.74% to $282.3 million in 2024, then tumbled by 58.34% to $117.6 million in 2025.
  • Its Other Operating Expenses stands at $117.6 million for Q4 2025, versus -$34.1 million for Q3 2025 and -$48.7 million for Q2 2025.